IN2013CN00515A - - Google Patents
Info
- Publication number
- IN2013CN00515A IN2013CN00515A IN515CHN2013A IN2013CN00515A IN 2013CN00515 A IN2013CN00515 A IN 2013CN00515A IN 515CHN2013 A IN515CHN2013 A IN 515CHN2013A IN 2013CN00515 A IN2013CN00515 A IN 2013CN00515A
- Authority
- IN
- India
- Prior art keywords
- compound
- enantiomers
- formula
- pharmaceutically acceptable
- acceptable salts
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 abstract 2
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
- C07D233/66—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D233/91—Nitro radicals
- C07D233/92—Nitro radicals attached in position 4 or 5
- C07D233/94—Nitro radicals attached in position 4 or 5 with hydrocarbon radicals, substituted by oxygen or sulfur atoms, attached to other ring members
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0014—Skin, i.e. galenical aspects of topical compositions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/10—Anti-acne agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Dermatology (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Rheumatology (AREA)
- Pain & Pain Management (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| FR1055241A FR2961809B1 (fr) | 2010-06-29 | 2010-06-29 | Esters de metronidazole pour traiter la rosacee |
| PCT/EP2011/060923 WO2012001053A1 (fr) | 2010-06-29 | 2011-06-29 | Ester de métronidazole pour le traitement de la rosacée |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IN2013CN00515A true IN2013CN00515A (fr) | 2015-07-03 |
Family
ID=42790955
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IN515CHN2013 IN2013CN00515A (fr) | 2010-06-29 | 2011-06-29 |
Country Status (23)
| Country | Link |
|---|---|
| US (1) | US8802710B2 (fr) |
| EP (1) | EP2588462B1 (fr) |
| JP (1) | JP2013529667A (fr) |
| KR (1) | KR20130088135A (fr) |
| CN (1) | CN102958920A (fr) |
| AR (1) | AR081783A1 (fr) |
| AU (1) | AU2011273498A1 (fr) |
| BR (1) | BR112012032490A2 (fr) |
| CA (1) | CA2801977A1 (fr) |
| CY (1) | CY1115622T1 (fr) |
| DK (1) | DK2588462T3 (fr) |
| ES (1) | ES2518119T3 (fr) |
| FR (1) | FR2961809B1 (fr) |
| HR (1) | HRP20140966T1 (fr) |
| IN (1) | IN2013CN00515A (fr) |
| MX (1) | MX2012014632A (fr) |
| PL (1) | PL2588462T3 (fr) |
| PT (1) | PT2588462E (fr) |
| RS (1) | RS53623B1 (fr) |
| RU (1) | RU2013103693A (fr) |
| SI (1) | SI2588462T1 (fr) |
| SM (1) | SMT201400174B (fr) |
| WO (1) | WO2012001053A1 (fr) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9715942B2 (en) | 2015-06-09 | 2017-07-25 | International Business Machines Corporation | Built-in self-test (BIST) circuit and associated BIST method for embedded memories |
| CN120309545A (zh) * | 2024-01-15 | 2025-07-15 | 中国药科大学 | 一种甲硝唑衍生物、制备方法及在药物制备中的应用 |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0127274A3 (fr) * | 1983-03-25 | 1987-05-20 | The Upjohn Company | Esters de métronidazole et compositions les contenant |
| IL142037A0 (en) * | 2001-03-15 | 2002-03-10 | Agis Ind 1983 Ltd | Pharmaceutical compositions containing a non-steroidal anti-inflammatory drug |
| WO2009058387A2 (fr) * | 2007-11-02 | 2009-05-07 | Nektar Therapeutics Al, Corporation | Conjugués anti-infectieux d'oligomère et de nitroimidazole |
-
2010
- 2010-06-29 FR FR1055241A patent/FR2961809B1/fr not_active Expired - Fee Related
-
2011
- 2011-06-29 RU RU2013103693/04A patent/RU2013103693A/ru not_active Application Discontinuation
- 2011-06-29 IN IN515CHN2013 patent/IN2013CN00515A/en unknown
- 2011-06-29 KR KR1020137001780A patent/KR20130088135A/ko not_active Withdrawn
- 2011-06-29 EP EP11729972.7A patent/EP2588462B1/fr not_active Not-in-force
- 2011-06-29 WO PCT/EP2011/060923 patent/WO2012001053A1/fr not_active Ceased
- 2011-06-29 CN CN2011800324626A patent/CN102958920A/zh active Pending
- 2011-06-29 PT PT117299727T patent/PT2588462E/pt unknown
- 2011-06-29 RS RS20140559A patent/RS53623B1/sr unknown
- 2011-06-29 PL PL11729972T patent/PL2588462T3/pl unknown
- 2011-06-29 AU AU2011273498A patent/AU2011273498A1/en not_active Abandoned
- 2011-06-29 JP JP2013517271A patent/JP2013529667A/ja active Pending
- 2011-06-29 AR ARP110102285A patent/AR081783A1/es unknown
- 2011-06-29 CA CA2801977A patent/CA2801977A1/fr not_active Abandoned
- 2011-06-29 MX MX2012014632A patent/MX2012014632A/es active IP Right Grant
- 2011-06-29 HR HRP20140966AT patent/HRP20140966T1/hr unknown
- 2011-06-29 DK DK11729972.7T patent/DK2588462T3/da active
- 2011-06-29 ES ES11729972.7T patent/ES2518119T3/es active Active
- 2011-06-29 US US13/806,719 patent/US8802710B2/en not_active Expired - Fee Related
- 2011-06-29 SI SI201130293T patent/SI2588462T1/sl unknown
- 2011-06-29 BR BR112012032490A patent/BR112012032490A2/pt not_active IP Right Cessation
-
2014
- 2014-10-13 CY CY20141100831T patent/CY1115622T1/el unknown
- 2014-11-13 SM SM201400174T patent/SMT201400174B/xx unknown
Also Published As
| Publication number | Publication date |
|---|---|
| AU2011273498A1 (en) | 2013-01-10 |
| CY1115622T1 (el) | 2017-01-04 |
| HRP20140966T1 (hr) | 2015-01-02 |
| FR2961809B1 (fr) | 2012-07-06 |
| KR20130088135A (ko) | 2013-08-07 |
| EP2588462A1 (fr) | 2013-05-08 |
| WO2012001053A1 (fr) | 2012-01-05 |
| PL2588462T3 (pl) | 2015-03-31 |
| BR112012032490A2 (pt) | 2016-12-13 |
| US8802710B2 (en) | 2014-08-12 |
| PT2588462E (pt) | 2014-10-30 |
| AR081783A1 (es) | 2012-10-17 |
| FR2961809A1 (fr) | 2011-12-30 |
| CN102958920A (zh) | 2013-03-06 |
| MX2012014632A (es) | 2013-02-07 |
| SI2588462T1 (sl) | 2015-02-27 |
| RS53623B1 (sr) | 2015-04-30 |
| CA2801977A1 (fr) | 2012-01-05 |
| JP2013529667A (ja) | 2013-07-22 |
| DK2588462T3 (da) | 2014-11-03 |
| ES2518119T3 (es) | 2014-11-04 |
| RU2013103693A (ru) | 2014-08-10 |
| US20130217740A1 (en) | 2013-08-22 |
| SMT201400174B (it) | 2015-01-15 |
| EP2588462B1 (fr) | 2014-08-13 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU2012313888A8 (en) | 3-pyrimidin-4-yl-oxazolidin-2-ones as inhibitors of mutant IDH | |
| PH12012501546A1 (en) | Substituted pyrrolidine-2-carboxamides | |
| MD20180040A2 (ro) | Inhibitori ai virusului hepatic C | |
| MY187718A (en) | Pharmaceutical formulations | |
| MY183312A (en) | Pharmaceutical formulation | |
| IN2012DN02487A (fr) | ||
| MY178150A (en) | Novel benzoic acid amide compound | |
| IN2014CN04449A (fr) | ||
| MX2011007978A (es) | Nuevo procedimiento de sintesis de la ivabradina y de sus sales de adicion a un acido farmaceuticamente aceptable. | |
| IN2014DN07996A (fr) | ||
| MX2010003213A (es) | Nuevo procedimiento de sintesis de la ivabradina y de sus sales de adicion a un acido farmaceuticamente aceptable. | |
| MY161749A (en) | Compound, certain novel forms thereof, pharmaceutical compositions thereof and methods for preparation and use | |
| MX2012002818A (es) | Nuevo procedimiento de sintesis de la ivabradina y de sus sales de adicion a un acido farmaceuticamente aceptable. | |
| MX2012007834A (es) | Derivados de acido carboxilico que comprenden un anillo de oxazolopirimidina 2,5-sustituido. | |
| MY178583A (en) | Hydantoin derivative | |
| MX359399B (es) | Inhibidores de 17alfa-hidroxilasa/c17-20-liasa. | |
| NZ605804A (en) | New aminopyrazoloquinazolines | |
| GB201020397D0 (en) | Compounds | |
| IN2012DE00289A (fr) | ||
| MX2010003184A (es) | Nuevo procedimiento de sinstesis de la ivabradina y de sus sales de adicion a un acido farmaceuticamente aceptable. | |
| MX2013009386A (es) | Nuevos compuestos de azaespirodecanona. | |
| JO2854B1 (en) | A new method for the synthesis of anfabradine and its added salts with acid is pharmaceutically acceptable. | |
| GEP20156269B (en) | New secondary 8-hydroxyquinoline-7- carboxamide derivatives | |
| PH12012502478A1 (en) | Isoquinoline derivative | |
| MX2013002656A (es) | Nuevo proceso. |